OncoMed Pharmaceuticals Inc
OMED evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- etigilimab (Phase 1)
What it means
What to watch
Prepared research question
What matters most for OMED—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 5 pipeline candidates for OncoMed Pharmaceuticals Inc.
Run OncoMed Pharmaceuticals Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OncoMed Pharmaceuticals Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is OncoMed Pharmaceuticals Inc's lead drug candidate?
OncoMed Pharmaceuticals Inc's most advanced tracked candidate is etigilimab (Phase 1) for Advanced or metastatic solid tumors.
Who is the CEO of OncoMed Pharmaceuticals Inc?
Redwood City is the chief executive officer of OncoMed Pharmaceuticals Inc (OMED).
What therapeutic areas does OncoMed Pharmaceuticals Inc focus on?
OncoMed Pharmaceuticals Inc develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.